Xvivo Perfusion AB
(LTS:0RKL)
kr
471.13141
-2.4818 (-0.52%)
Market Cap: 15.12 Bil
Enterprise Value: 14.69 Bil
PE Ratio: 73.15
PB Ratio: 7.28
GF Score: 89/100 Q3 2020 Xvivo Perfusion AB Earnings Call Transcript
Oct 23, 2020 / 12:30PM GMT
Release Date Price:
kr235.5
(-2.28%)
Ulrik Trattner
Carnegie Investment Bank AB, Research Division - Research Analyst
Great. I see that the clock is already half past 2, so I think we'll start off this presentation. And my name is Ulrik Trattner, research analyst at Carnegie. And we are very pleased today to host the Q3 conference call for XVIVO Perfusion. And presenting the company today is CEO, Dag Andersson; as well as EFO and -- or should we call you CFO, Christoffer? Or would you like to go under a new title?
Christoffer Rosenblad;publ;COO;Board Secretary
Xvivo Perfusion AB
()-&
No, no, no. Ulrik, it's fine.
Ulrik Trattner
Carnegie Investment Bank AB, Research Division - Research Analyst
Great. Well, I'll hand over to you, guys. (Operator Instructions) By that, I will over -- leave over to you. Thank you very much.
Dag Andersson;publ;President;CEO
Xvivo Perfusion AB
()-&
Thank you, Ulrik. So yes,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot